Related Experiment Videos
[Antimetabolites in glaucoma surgery--long-term results]
L Michalíková1, S Ferková, E Jakabovicová
1Ocná klinika FN a LFUK, Bratislava.
Summary
Antimetabolites like 5-Fluorouracil (5-FU) and Mitomycin C (MMC) improve glaucoma filtering surgery success rates in high-risk patients. Long-term follow-up confirms their efficacy, though filtration failure remains a challenge.
Area of Science:
- Ophthalmology
- Surgical Innovation
- Glaucoma Research
Context:
- Glaucoma filtering surgery success is often limited in high-risk eyes.
- Antimetabolites are used to enhance surgical outcomes.
- Previous studies show variable long-term efficacy.
Purpose:
- To evaluate the long-term success of antimetabolites (5-FU and MMC) in glaucoma filtering surgery.
- To assess the efficacy in eyes with a high risk of surgical failure.
- To compare the outcomes of 5-FU and MMC in trabeculectomy.
Summary:
- This retrospective study compared 5-Fluorouracil (5-FU) and Mitomycin C (MMC) in trabeculectomy for high-risk glaucoma.
- 5-FU (n=32) was administered postoperatively, while MMC (n=15) was used intraoperatively.
- Long-term follow-up (up to 9 years for 5-FU, 4.5 years for MMC) showed success rates of 79.2% for 5-FU and 83.3% for MMC (IOP ≤ 20 mmHg).
Impact:
- Antimetabolites significantly reduce intraocular pressure (IOP) post-glaucoma surgery.
- Both 5-FU and MMC demonstrate comparable long-term effectiveness in high-risk glaucoma patients.
- Filtration failure remains a significant clinical issue despite antimetabolite use.